Andrea R Sabbatini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8778660/publications.pdf

Version: 2024-02-01

840776 888059 17 418 11 17 citations h-index g-index papers 17 17 17 809 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Menopause-Related Estrogen Decrease and the Pathogenesis of HFpEF. Journal of the American College of Cardiology, 2020, 75, 1074-1082.	2.8	76
2	Estrogen-related mechanisms in sex differences of hypertension and target organ damage. Biology of Sex Differences, 2020, 11, 31.	4.1	62
3	An update on the role of adipokines in arterial stiffness and hypertension. Journal of Hypertension, 2015, 33, 435-444.	0.5	42
4	Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension. Hypertension Research, 2013, 36, 1067-1072.	2.7	39
5	Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. Journal of the American Society of Hypertension, 2015, 9, 397-402.	2.3	36
6	Plasma 8-isoprostane levels are associated with endothelial dysfunction in resistant hypertension. Clinica Chimica Acta, 2014, 433, 179-183.	1.1	31
7	Modulation of aldosterone levels by â^344ÂC/T CYP11B2 polymorphism and spironolactone use in resistant hypertension. Journal of the American Society of Hypertension, 2014, 8, 146-151.	2.3	23
8	Increased Circulating Tissue Inhibitor of Metalloproteinaseâ€2 Is Associated With Resistant Hypertension. Journal of Clinical Hypertension, 2016, 18, 969-975.	2.0	20
9	A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. Journal of the American Society of Hypertension, 2016, 10, 510-516.e1.	2.3	15
10	Crosstalk between obesity and MMP-9 in cardiac remodelling –a cross-sectional study in apparent treatment-resistant hypertension. Blood Pressure, 2017, 26, 122-129.	1.5	15
11	Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension. American Journal of Hypertension, 2016, 29, 245-250.	2.0	11
12	Adiponectin $\hat{a} \in 1377$ C/G and $+276$ G/T Polymorphisms affect Adiponectin Levels but do not Modify Responsiveness to Therapy in Resistant Hypertension. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 65-72.	2.5	10
13	Effects of leptin and leptin receptor SNPs on clinical- and metabolic-related traits in apparent treatment-resistant hypertension. Blood Pressure, 2017, 26, 74-80.	1.5	10
14	Matrix metalloproteinase-2 â^ 735C/T polymorphism is associated with resistant hypertension in a specialized outpatient clinic in Brazil. Gene, 2017, 620, 23-29.	2.2	10
15	The rs243866/243865 polymorphisms in MMP-2 gene and the relationship with BP control in obese resistant hypertensive subjects. Gene, 2018, 646, 129-135.	2.2	7
16	Predictors of Silent Myocardial Ischemia in Resistant Hypertensive Patients. American Journal of Hypertension, 2015, 28, 200-207.	2.0	6
17	The effect of two selective A ₁ â€receptor agonists and the bitopic ligand <scp>VCP746</scp> on heart rate and regional vascular conductance in conscious rats. British Journal of Pharmacology, 2020, 177, 346-359.	5.4	5